Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers

Early breast cancer; Hormone receptor status; Young patients

Detalles Bibliográficos
Autores: Bas, Raphaëlle, Kim, Heejeong, Di Meglio, Antonio, Bernstein Molho, Rinat, Arecco, Luca, Bruzzone, Marco, Carrasco Lopez, Estela
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:11351/11987
Acceso en línea:https://hdl.handle.net/11351/11987
http://hdl.handle.net/11351/11987
Access Level:acceso abierto
Palabra clave:Anomalies cromosòmiques
Mama - Càncer - Aspectes genètics
Mama - Càncer - Prognosi
Gens del càncer
DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms
Other subheadings::Other subheadings::Other subheadings::/genetics
PHENOMENA AND PROCESSES::Genetic Phenomena::Genetic Variation::Mutation
PHENOMENA AND PROCESSES::Genetic Phenomena::Genetic Structures::Genome::Genome Components::Genes::Genes, Neoplasm::Genes, Tumor Suppressor::Genes, BRCA1
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama
Otros calificadores::Otros calificadores::Otros calificadores::/genética
FENÓMENOS Y PROCESOS::fenómenos genéticos::variación genética::mutación
FENÓMENOS Y PROCESOS::fenómenos genéticos::estructuras genéticas::genoma::componentes genómicos::genes::genes de neoplasias::genes supresores de tumores::genes BRCA1
id ES_fa37b5f9ee1a64ae31f25a3be3d2eead
oai_identifier_str oai:recercat.cat:11351/11987
network_acronym_str ES
network_name_str España
repository_id_str
dc.title.none.fl_str_mv Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers
title Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers
spellingShingle Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers
Bas, Raphaëlle
Anomalies cromosòmiques
Mama - Càncer - Aspectes genètics
Mama - Càncer - Prognosi
Gens del càncer
DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms
Other subheadings::Other subheadings::Other subheadings::/genetics
PHENOMENA AND PROCESSES::Genetic Phenomena::Genetic Variation::Mutation
PHENOMENA AND PROCESSES::Genetic Phenomena::Genetic Structures::Genome::Genome Components::Genes::Genes, Neoplasm::Genes, Tumor Suppressor::Genes, BRCA1
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama
Otros calificadores::Otros calificadores::Otros calificadores::/genética
FENÓMENOS Y PROCESOS::fenómenos genéticos::variación genética::mutación
FENÓMENOS Y PROCESOS::fenómenos genéticos::estructuras genéticas::genoma::componentes genómicos::genes::genes de neoplasias::genes supresores de tumores::genes BRCA1
title_short Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers
title_full Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers
title_fullStr Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers
title_full_unstemmed Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers
title_sort Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers
dc.creator.none.fl_str_mv Bas, Raphaëlle
Kim, Heejeong
Di Meglio, Antonio
Bernstein Molho, Rinat
Arecco, Luca
Bruzzone, Marco
Carrasco Lopez, Estela
author Bas, Raphaëlle
author_facet Bas, Raphaëlle
Kim, Heejeong
Di Meglio, Antonio
Bernstein Molho, Rinat
Arecco, Luca
Bruzzone, Marco
Carrasco Lopez, Estela
author_role author
author2 Kim, Heejeong
Di Meglio, Antonio
Bernstein Molho, Rinat
Arecco, Luca
Bruzzone, Marco
Carrasco Lopez, Estela
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv Institut Català de la Salut
[Arecco L] Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genova, Genova, Italy. Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Academic Trials Promoting Team, Bruxelles, Belgium. [Bruzzone M] U.O. Epidemiologia Clinica, IRCCS Ospedale Policlinico San Martino, Genova, Italy. [Bas R] Department of Surgery, Universite Paris Cité, Institut Curie, Paris, France. [Kim HJ] Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. [Di Meglio A] Cancer Survivorship Program—Molecular Predicitors and New Targets in Oncology, INSERM Unit 981, Gustave Roussy, Villejuif, France. [Bernstein-Molho R] Susanne Levy Gertner Oncogenetics Unit, The Danek Gertner Institute of Human Genetics, Chaim Sheba Medical Center Affiliated to Tel Aviv University, Tel Hashomer, Israel. [Carrasco E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Hereditary Cancer Genetics Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
dc.subject.none.fl_str_mv Anomalies cromosòmiques
Mama - Càncer - Aspectes genètics
Mama - Càncer - Prognosi
Gens del càncer
DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms
Other subheadings::Other subheadings::Other subheadings::/genetics
PHENOMENA AND PROCESSES::Genetic Phenomena::Genetic Variation::Mutation
PHENOMENA AND PROCESSES::Genetic Phenomena::Genetic Structures::Genome::Genome Components::Genes::Genes, Neoplasm::Genes, Tumor Suppressor::Genes, BRCA1
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama
Otros calificadores::Otros calificadores::Otros calificadores::/genética
FENÓMENOS Y PROCESOS::fenómenos genéticos::variación genética::mutación
FENÓMENOS Y PROCESOS::fenómenos genéticos::estructuras genéticas::genoma::componentes genómicos::genes::genes de neoplasias::genes supresores de tumores::genes BRCA1
topic Anomalies cromosòmiques
Mama - Càncer - Aspectes genètics
Mama - Càncer - Prognosi
Gens del càncer
DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms
Other subheadings::Other subheadings::Other subheadings::/genetics
PHENOMENA AND PROCESSES::Genetic Phenomena::Genetic Variation::Mutation
PHENOMENA AND PROCESSES::Genetic Phenomena::Genetic Structures::Genome::Genome Components::Genes::Genes, Neoplasm::Genes, Tumor Suppressor::Genes, BRCA1
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama
Otros calificadores::Otros calificadores::Otros calificadores::/genética
FENÓMENOS Y PROCESOS::fenómenos genéticos::variación genética::mutación
FENÓMENOS Y PROCESOS::fenómenos genéticos::estructuras genéticas::genoma::componentes genómicos::genes::genes de neoplasias::genes supresores de tumores::genes BRCA1
description Early breast cancer; Hormone receptor status; Young patients
publishDate 2024
dc.date.none.fl_str_mv 2024
2024
2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11351/11987
http://hdl.handle.net/11351/11987
url https://hdl.handle.net/11351/11987
http://hdl.handle.net/11351/11987
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Annals of Oncology;35(9)
https://doi.org/10.1016/j.annonc.2024.06.009
dc.rights.none.fl_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv Scientia
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869425164831162368
spelling Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriersBas, RaphaëlleKim, HeejeongDi Meglio, AntonioBernstein Molho, RinatArecco, LucaBruzzone, MarcoCarrasco Lopez, EstelaAnomalies cromosòmiquesMama - Càncer - Aspectes genèticsMama - Càncer - PrognosiGens del càncerDISEASES::Neoplasms::Neoplasms by Site::Breast NeoplasmsOther subheadings::Other subheadings::Other subheadings::/geneticsPHENOMENA AND PROCESSES::Genetic Phenomena::Genetic Variation::MutationPHENOMENA AND PROCESSES::Genetic Phenomena::Genetic Structures::Genome::Genome Components::Genes::Genes, Neoplasm::Genes, Tumor Suppressor::Genes, BRCA1ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mamaOtros calificadores::Otros calificadores::Otros calificadores::/genéticaFENÓMENOS Y PROCESOS::fenómenos genéticos::variación genética::mutaciónFENÓMENOS Y PROCESOS::fenómenos genéticos::estructuras genéticas::genoma::componentes genómicos::genes::genes de neoplasias::genes supresores de tumores::genes BRCA1Early breast cancer; Hormone receptor status; Young patientsCáncer de mama temprano; Estado del receptor hormonal; Pacientes jóvenesCàncer de mama precoç; Estat del receptor hormonal; Pacients jovesBackground Hormone receptor expression is a known positive prognostic and predictive factor in breast cancer; however, limited evidence exists on its prognostic impact on prognosis of young patients harboring a pathogenic variant (PV) in the BRCA1 and/or BRCA2 genes. Patients and methods This international, multicenter, retrospective cohort study included young patients (aged ≤40 years) diagnosed with invasive breast cancer and harboring germline PVs in BRCA genes. We investigated the impact of hormone receptor status on clinical behavior and outcomes of breast cancer. Outcomes of interest [disease-free survival (DFS), breast cancer-specific survival (BCSS), and overall survival (OS)] were first investigated according to hormone receptor expression (positive versus negative), and then according to breast cancer subtype [luminal A-like versus luminal B-like versus triple-negative versus human epidermal growth factor receptor 2 (HER2)-positive breast cancer]. Results From 78 centers worldwide, 4709 BRCA carriers were included, of whom 2143 (45.5%) had hormone receptor-positive and 2566 (54.5%) hormone receptor-negative breast cancer. Median follow-up was 7.9 years. The rate of distant recurrences was higher in patients with hormone receptor-positive disease (13.1% versus 9.6%, P < 0.001), while the rate of second primary breast cancer was lower (9.1% versus 14.7%, P < 0.001) compared to patients with hormone receptor-negative disease. The 8-year DFS was 65.8% and 63.4% in patients with hormone receptor-positive and negative disease, respectively. The hazard ratio of hormone receptor-positive versus negative disease changed over time for DFS, BCSS, and OS (P < 0.05 for interaction of hormone receptor status and survival time). Patients with luminal A-like breast cancer had the worst long-term prognosis in terms of DFS compared to all the other subgroups (8-year DFS: 60.8% in luminal A-like versus 63.5% in triple-negative versus 65.5% in HER2-positive and 69.7% in luminal B-like subtype). Conclusions In young BRCA carriers, differences in recurrence pattern and second primary breast cancer among hormone receptor-positive versus negative disease warrant consideration in counseling patients on treatment, follow-up, and risk-reducing surgery.The study was partly supported by the Italian Association for Cancer Research (AIRC grant) [grant number MFAG 2020 ID 24698] ML received support from the European Society for Medical Oncology (ESMO) for a translational research fellowship at the Institut Jules Bordet in Brussels, Belgium, at the time this study was initiated. HJK received support from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea [grant number HC20C0135]. KAP is an Australian National Health and Medical Research Council leadership fellow. Data collection for most Australian participants was through the kConFab Follow-Up Study with support from Cancer Australia and the National Breast Cancer Foundation [grant number PdCCRS 1100868], Cancer Australia [grant number 809195], the Australian National Breast Cancer Foundation (IF 17), the Australian National Health and Medical Research Council [grant numbers 454508, 288704, 145684], the US National Institutes of Health [grant number 1RO1CA159868], the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia, and the Cancer Foundation of Western Australia. NIH R35CA253187, P50CA116201 SPORE in Breast Cancer, and Breast Cancer Research Foundation. AHP received support from the Breast Cancer Research Foundation and Susan G. Komen. FJC was supported by NIH grants R35CA253187 and P50CA115201 and the Breast Cancer research Foundation. The study supporters had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.ElsevierInstitut Català de la Salut[Arecco L] Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genova, Genova, Italy. Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Academic Trials Promoting Team, Bruxelles, Belgium. [Bruzzone M] U.O. Epidemiologia Clinica, IRCCS Ospedale Policlinico San Martino, Genova, Italy. [Bas R] Department of Surgery, Universite Paris Cité, Institut Curie, Paris, France. [Kim HJ] Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. [Di Meglio A] Cancer Survivorship Program—Molecular Predicitors and New Targets in Oncology, INSERM Unit 981, Gustave Roussy, Villejuif, France. [Bernstein-Molho R] Susanne Levy Gertner Oncogenetics Unit, The Danek Gertner Institute of Human Genetics, Chaim Sheba Medical Center Affiliated to Tel Aviv University, Tel Hashomer, Israel. [Carrasco E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Hereditary Cancer Genetics Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, SpainVall d'Hebron Barcelona Hospital Campus202420242024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/11351/11987http://hdl.handle.net/11351/11987Scientiareponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésAnnals of Oncology;35(9)https://doi.org/10.1016/j.annonc.2024.06.009Attribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:11351/119872026-05-29T05:05:01Z
score 15,81155

Similares en LA Referencia